Bio-Rad buys Curiosity Diagnostics for up to $170M
Bio-Rad will gain Curiosity Diagnostics' PCR|One platform, a sample-to-answer, rapid diagnostics PCR system under development.
Stay updated with breaking news from Scope Fluidics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bio-Rad will gain Curiosity Diagnostics' PCR|One platform, a sample-to-answer, rapid diagnostics PCR system under development.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an agreement to acquire all of the outstanding
Newly merged with a firm founded by BioFire Diagnostics alums, Co-Diagnostics plans to develop small panels for the system with up to six targets.
Share this article Share this article ResearchAndMarkets.com's offering. The diagnosis and treatment of sepsis is one of the biggest challenges facing healthcare currently. In the United States, there are around 1.7 million cases of sepsis per year, resulting in approximately 270,000 deaths. Overall, the costs associated with sepsis make it the most expensive condition treated in US hospitals. This report provides comprehensive information on products in the sepsis market, as well as: Sepsis Detection Practice Trends Markets for Sepsis-Related Testing COVID-19 and Sepsis Sepsis Testing Pro...